Cargando…

A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes

AIMS: Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Yingying, Wang, Hongyuan, Zhou, Xianghai, Chang, Cuiqing, Chen, Wei, Guo, Xiaohui, Yang, Jinkui, Ji, Linong, Paul, Sanjoy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759441/
https://www.ncbi.nlm.nih.gov/pubmed/35036447
http://dx.doi.org/10.1155/2022/2971382
_version_ 1784633109139947520
author Luo, Yingying
Wang, Hongyuan
Zhou, Xianghai
Chang, Cuiqing
Chen, Wei
Guo, Xiaohui
Yang, Jinkui
Ji, Linong
Paul, Sanjoy K.
author_facet Luo, Yingying
Wang, Hongyuan
Zhou, Xianghai
Chang, Cuiqing
Chen, Wei
Guo, Xiaohui
Yang, Jinkui
Ji, Linong
Paul, Sanjoy K.
author_sort Luo, Yingying
collection PubMed
description AIMS: Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored whether these interventions could revert prediabetes to normal glycemic status as the primary outcome. Interventions that may revert prediabetes back to normal glucose status would be of great clinical importance. MATERIALS AND METHODS: We conducted a randomized, multicenter, 2 × 2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance. The participants were followed up for three years unless they reverted to normal glucose state or developed diabetes at the annual oral glucose tolerance test (OGTT). Reversion to normal glucose tolerance was confirmed on the basis of the results of OGTT. RESULTS: In our study, 1945 eligible patients were ultimately randomized into four groups. In this three-year follow-up study, overall, 60.0%, 50.3%, 56.6% and 65.1% reverted back to normoglycemic state over 3 years of follow-up in the conventional lifestyle intervention plus placebo, intensive lifestyle intervention plus placebo, conventional lifestyle intervention plus pioglitazone, and intensive lifestyle intervention plus pioglitazone groups, respectively. Compared to the conventional lifestyle intervention plus placebo group, all the other three groups did not show any significant benefit in terms of reverting back to normoglycemic state. CONCLUSION: In our study, for patients with prediabetes, neither intensive lifestyle intervention nor pioglitazone had led to a higher reversion rate to normal glucose state. Trail registration.http://www.chictr.org.cn: ChiCTR-PRC-06000005.
format Online
Article
Text
id pubmed-8759441
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87594412022-01-15 A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes Luo, Yingying Wang, Hongyuan Zhou, Xianghai Chang, Cuiqing Chen, Wei Guo, Xiaohui Yang, Jinkui Ji, Linong Paul, Sanjoy K. J Diabetes Res Research Article AIMS: Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored whether these interventions could revert prediabetes to normal glycemic status as the primary outcome. Interventions that may revert prediabetes back to normal glucose status would be of great clinical importance. MATERIALS AND METHODS: We conducted a randomized, multicenter, 2 × 2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance. The participants were followed up for three years unless they reverted to normal glucose state or developed diabetes at the annual oral glucose tolerance test (OGTT). Reversion to normal glucose tolerance was confirmed on the basis of the results of OGTT. RESULTS: In our study, 1945 eligible patients were ultimately randomized into four groups. In this three-year follow-up study, overall, 60.0%, 50.3%, 56.6% and 65.1% reverted back to normoglycemic state over 3 years of follow-up in the conventional lifestyle intervention plus placebo, intensive lifestyle intervention plus placebo, conventional lifestyle intervention plus pioglitazone, and intensive lifestyle intervention plus pioglitazone groups, respectively. Compared to the conventional lifestyle intervention plus placebo group, all the other three groups did not show any significant benefit in terms of reverting back to normoglycemic state. CONCLUSION: In our study, for patients with prediabetes, neither intensive lifestyle intervention nor pioglitazone had led to a higher reversion rate to normal glucose state. Trail registration.http://www.chictr.org.cn: ChiCTR-PRC-06000005. Hindawi 2022-01-06 /pmc/articles/PMC8759441/ /pubmed/35036447 http://dx.doi.org/10.1155/2022/2971382 Text en Copyright © 2022 Yingying Luo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Luo, Yingying
Wang, Hongyuan
Zhou, Xianghai
Chang, Cuiqing
Chen, Wei
Guo, Xiaohui
Yang, Jinkui
Ji, Linong
Paul, Sanjoy K.
A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title_full A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title_fullStr A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title_full_unstemmed A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title_short A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
title_sort randomized controlled clinical trial of lifestyle intervention and pioglitazone for normalization of glucose status in chinese with prediabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759441/
https://www.ncbi.nlm.nih.gov/pubmed/35036447
http://dx.doi.org/10.1155/2022/2971382
work_keys_str_mv AT luoyingying arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT wanghongyuan arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT zhouxianghai arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT changcuiqing arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT chenwei arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT guoxiaohui arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT yangjinkui arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT jilinong arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT paulsanjoyk arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT luoyingying randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT wanghongyuan randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT zhouxianghai randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT changcuiqing randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT chenwei randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT guoxiaohui randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT yangjinkui randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT jilinong randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes
AT paulsanjoyk randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes